Detalles de la búsqueda
1.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Blood
; 140(9): 980-991, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35687757
2.
Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency.
Am J Hematol
; 99(7): 1415-1419, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38712615
3.
Glycolytic activity and in vitro effect of the pyruvate kinase activator AG-946 in red blood cells from low-risk myelodysplastic syndromes patients: A proof-of-concept study.
Am J Hematol
; 99(6): 1201-1204, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38563490
4.
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Eur J Haematol
; 110(3): 280-288, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36403132
5.
Complement-mediated hemolysis persists year round in patients with cold agglutinin disease.
Transfusion
; 62(1): 51-59, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34813663
6.
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Haematologica
; 107(7): 1698-1702, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172561
7.
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
Blood Adv
; 8(10): 2433-2441, 2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330179
8.
Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States.
PLoS One
; 17(12): e0276617, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36520848
Resultados
1 -
8
de 8
1
Próxima >
>>